Keryx soars following more good news for Zerenex

• Keryx Biopharmaceuticals (NASDAQ:KERX) jumps 15.6% premarket as Zerenex meets all primary and key secondary endpoints in a Phase 2 study.
• The trial tested Zerenex in non-dialysis dependent chronic kidney disease patients with elevated serum phosphorus and iron deficiency anemia.
• Mean changes in serum phosphorus: Baseline was 4.7 for placebo and 4.5 for Zerenex, EOT was 4.4 for placebo and 3.9 for Zerenex. Mean changes in TSAT: Baseline was 21 for placebo and 22 for Zerenex, EOT was 20 for placebo and 32 for Zerenex.
• KERX says it "plans to meet with the FDA to discuss these data with the goal of defining a path forward towards obtaining a labeled indication." (PR)
• See also: KERX Q3 results and PR.